SEATTLE, WA and SUNNYVALE, CA – Calypso Medical and IMPAC Medical Systems, an Elekta company, have identified product collaboration projects which will further enable integration of oncology management systems with the Calypso® 4D Localization System™.
Lilly to Acquire Phase III Molecule Teplizumab for the Treatment of Type 1 Diabetes Companies to Collaborate on the Development of Autoimmune Disease Treatments INDIANAPOLIS, IN and ROCKVILLE, MD – Eli Lilly and Company (NYSE:LLY) and MacroGenics, Inc. today announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, […]
RiverVest Venture Partners®, a venture capital firm investing nationwide in emerging medical technology and biopharmaceutical companies, today announced that Gordon Foulkes, Ph.D., has joined the firm as a Venture Partner.
RiverVest Venture Partners®, a venture capital firm investing nationwide in emerging medical technology and biopharmaceutical companies, has named Dennis Wahr, M.D., to the position of managing director. Wahr, a specialist in cardiac medicine, brings to the firm more than 25 years of experience in clinical practice and medical device entrepreneurship.
RiverVest Venture Partners, a national venture capital firm focusing on seed and early-stage life sciences investments, has named Scott R. Naisbitt, M.D., Ph.D. an associate and Floyd E. Bloom, M.D., a scientific advisor. Dr. Naisbitt brings a broad background in molecular biology, neuroscience and clinical medicine to RiverVest. Prior to joining the firm, he was an associate of Seedling Enterprises…
RiverVest Venture Partners announced today that the fundraising for RiverVest Venture Fund I, L.P. is complete, closing with $89 million of capital under management. The firm’s founders and managing directors are Andrew B. Craig III, Thomas C. Melzer, Jay W. Schmelter and Mark J. Mendel, Ph.D.